Skip to content

Three Quick Facts: Music Magpie, Immupharma, Barryroe


Three things you need to know in the financial markets today from investment writer, Tony Cross.

#1. Music Magpie: after difficult Q1, performance improving

Music Magpie [LON:MMAG] has published a trading update covering the six months to 31st May. Noting weak consumer confidence and the impact of postal strikes during Q1, the picture improved during Q2. EBITDA performance for the first half was up 7.7% and in line with management expectations. The company envisages that as is usual, seasonal patterns will help H2 performance and that the pivot towards higher margin sales will help deliver an on target FY despite economic headwinds.

#2. Immupharma: next phase of clinical trials underway

Immupharma [LON:IMM] has announced that the next phase of its clinical trial of a Lupus therapy is to commence in the second half of the year, following the receipt of detailed guidance from the FDA. This is for a phase 2/3 adaptive clinical trial that will include dosing at much higher concentrations with significant changes to patient inclusion criteria and primary and secondary clinical endpoints.

#3. Barryroe shares suspended

Followers of our Small Cap roundup may recall Barryroe [LON:BEY], the offshore energy firm which ran into a significant roadblock from the Irish government over drilling licenses, despite secured funding for the project being held in escrow. Talks are underway with shareholders to see if funding for day to day operations can be secured but failing this the company has by now initiated a Creditors Voluntary Liquidation process and shares have been suspended. This could well play out for some time yet.

Looking for great investing ideas? Sign up to our free newsletter.

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top